What is IMNM's current stock price?

As of now, IMNM is trading at $20.40, with a daily change of +1.65%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

IMNM Stock Analysis & IQ Rating | Immunome

IMNM IMNM Badge

Immunome

$20.40

+$0.45 | +1.65%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$25.3

MKT CAP

$2.24B

52W Low

$5.15

VOL

$402.25K

P/E Ratio

N/A

AVG VOL

$2.12M

RSI

55.92

TREND

Uptrend

IMNM Stock IQ

Login to see Immunome (IMNM) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

IMNM Target Price

Login to display

Strengths

IMNM Rewards

Upgraded on attractively valued

IMNM Rewards

Earnings are forecast to grow

IMNM Price Performance

$18.53 (+10.09%)

$10.15 (+100.99%)

$10.75 (+89.77%)

$11.27 (+81.01%)

1year

6month

3month

1month

IMNM Risk Level

IMNM has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

High volatilty

Extreme

LOW

HIGH

IMNM Analysts Opinion

IMNM overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

IMNM Analysts Opinion

IMNM Analysts opinion is positive and also has improved from the past 3 months

IMNM Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

92%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

IMNM Street Sentiment

IMNM Street Sentiment is extremely bullish and have positive views on the near-term outlook

IMNM Performance Sentiment

Sentiments overview associated with IMNM events and the stock performance.

92%

8%

Positive

Negative

12 out of 13
events present

1 out of 13
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$19.82

Resistance
Price

$16.64

Current Price Range

$23.48

Show methods +

IMNM Latest Analysis +

Immunome prices $400M stock offering at $21.50 a share.

Wed Dec 17, 2025

$19.78 | -15.76%

Activity

Whats Going On With Immunome Shares Monday?. IMNM) shares are trading higher on Monday after the company announced results from the global pivotal Phase 3 RINGSIDE trial of varegcasetat and the company met its primary endpoint.The registrational trial met its ...

Mon Dec 15, 2025

$22.64 | +15.69%

Momentum

Why Immunome Stock Surged Today. Key PointsA phase 3 study of varegacestat met its primary endpoint.

Mon Dec 15, 2025

$22.64 | +15.69%

Momentum

Immunome announces proposed public offering.

Mon Dec 15, 2025

$22.64 | +15.69%

Activity

Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug . (RTTNews) - Immunome Inc. (IMNM) shares jumped 20.44% rising $4.00 to close at $23.57 following the companys announcement of positive topline results from its Phase 3 RINGSIDE trial evaluating varegacestat in patients with desmoid tumors.

Mon Dec 15, 2025

$22.64 | +15.69%

Activity

Momentum

Immunome A Top 3% Stock Just Delivered A Knockout To Merck KGaA. Top-notch biotech stock Immunome rocketed Monday after the companys treatment for desmoid tumors appeared to top an approved drug.The post Immunome A Top 3% Stock Just Delivered A '.Knockout'. To Merck KGaA appeared first on Investor'.s Business Daily.

Mon Dec 15, 2025

$22.64 | +15.69%

Momentum

Why Is Immunome Stock Soaring Monday?. IMNM) stock rose Monday with session volume surging to 8.25 million shares well above the stock’.s average daily volume of 1.50 million according to data.Immunome on Monday shared topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat for .A desmoid tumor also known as aggressive fibromatosis is a rare noncancerous growth in connective tissue often in the abdomen arms or legs that is locally aggressive (infiltrates surrounding

Mon Dec 15, 2025

$22.64 | +15.69%

Momentum

Immunomes Varegacestat Meets Phase-3 Endpoints In Desmoid Tumors- Update . (RTTNews) - Immunome Inc. (IMNM) Monday reported positive data from its pivotal Phase-3 RINGSIDE trial in patients with desmoid tumors with Varegacestat improving progression-free survival and meeting all key secondary endpoints.

Mon Dec 15, 2025

$22.64 | +15.69%

Activity

Potential

Truist Securities Initiates Coverage of Immunome (IMNM) with Buy Recommendation. Fintel reports that on December 1 2025 Truist Securities initiated coverage of Immunome (NasdaqCM:IMNM) with a Buy recommendation. Analyst Price Forecast Suggests 32.90% Upside

Mon Dec 1, 2025

$18.32 | -0.54%

Rating

FAQ About IMNM Stock Insights

What is IMNM current stock price?

What are IMNM stock strengths?

What is IMNM Risk Level?

What is IMNM market cap and volume?

What is IMNM current Stock IQ?

Should I buy IMNM stock right now?

Is IMNM a Strong Buy right now?

What does a 'Strong Buy' rating mean for IMNM?

What does a 'Strong Sell' rating mean for IMNM?

What factors influence IMNM's Stock IQ?

Explore our IMNM Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored IMNM Stock Strategies
Effective Risk Management

FIND US ON

Receive our IMNM Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

IMNM IMNM Badge

Immunome

Current Price

$20.40

+$0.45 | +1.65%

52W High

$25.3

MKT CAP

$2.24B

52W Low

$5.15

VOL

$402.25K

P/E Ratio

N/A

AVG VOL

$2.12M

RSI

55.92

TREND

Uptrend

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

IMNM Rewards

Upgraded on attractively valued

IMNM Rewards

Earnings are forecast to grow

IMNM Price Performance

$18.53 (+10.09%)

$10.15 (+100.99%)

$10.75 (+89.77%)

$11.27 (+81.01%)

1year

6month

3month

1month

IMNM Analysts Opinion

IMNM Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

IMNM Analysts Opinion

IMNM Analysts opinion is positive and also has improved from the past 3 months

IMNM Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

92%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

IMNM Street Sentiment

IMNM Street Sentiment is extremely bullish and have positive views on the near-term outlook

IMNM Risk Level

IMNM has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

High volatilty

Extreme

LOW

HIGH

IMNM Performance Sentiment

Sentiments overview associated with IMNM events and the stock performance.

92%

8%

Positive

Negative

12 out of 13
events present

1 out of 13
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$19.82

Resistance
Price

$16.64

Current Price Range

$23.48

Show methods +

IMNM Stock IQ

Login to unlock Immunome (IMNM) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

IMNM Latest Analysis

Immunome prices $400M stock offering at $21.50 a share.

Wed Dec 17, 2025

$19.78 | -15.76%

Activity

Whats Going On With Immunome Shares Monday?. IMNM) shares are trading higher on Monday after the company announced results from the global pivotal Phase 3 RINGSIDE trial of varegcasetat and the company met its primary endpoint.The registrational trial met its ...

Mon Dec 15, 2025

$22.64 | +15.69%

Momentum

Why Immunome Stock Surged Today. Key PointsA phase 3 study of varegacestat met its primary endpoint.

Mon Dec 15, 2025

$22.64 | +15.69%

Momentum

Immunome announces proposed public offering.

Mon Dec 15, 2025

$22.64 | +15.69%

Activity

Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug . (RTTNews) - Immunome Inc. (IMNM) shares jumped 20.44% rising $4.00 to close at $23.57 following the companys announcement of positive topline results from its Phase 3 RINGSIDE trial evaluating varegacestat in patients with desmoid tumors.

Mon Dec 15, 2025

$22.64 | +15.69%

Activity

Momentum

Immunome A Top 3% Stock Just Delivered A Knockout To Merck KGaA. Top-notch biotech stock Immunome rocketed Monday after the companys treatment for desmoid tumors appeared to top an approved drug.The post Immunome A Top 3% Stock Just Delivered A '.Knockout'. To Merck KGaA appeared first on Investor'.s Business Daily.

Mon Dec 15, 2025

$22.64 | +15.69%

Momentum

Why Is Immunome Stock Soaring Monday?. IMNM) stock rose Monday with session volume surging to 8.25 million shares well above the stock’.s average daily volume of 1.50 million according to data.Immunome on Monday shared topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat for .A desmoid tumor also known as aggressive fibromatosis is a rare noncancerous growth in connective tissue often in the abdomen arms or legs that is locally aggressive (infiltrates surrounding

Mon Dec 15, 2025

$22.64 | +15.69%

Momentum

Immunomes Varegacestat Meets Phase-3 Endpoints In Desmoid Tumors- Update . (RTTNews) - Immunome Inc. (IMNM) Monday reported positive data from its pivotal Phase-3 RINGSIDE trial in patients with desmoid tumors with Varegacestat improving progression-free survival and meeting all key secondary endpoints.

Mon Dec 15, 2025

$22.64 | +15.69%

Activity

Potential

Truist Securities Initiates Coverage of Immunome (IMNM) with Buy Recommendation. Fintel reports that on December 1 2025 Truist Securities initiated coverage of Immunome (NasdaqCM:IMNM) with a Buy recommendation. Analyst Price Forecast Suggests 32.90% Upside

Mon Dec 1, 2025

$18.32 | -0.54%

Rating

Discover IMNM Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of IMNM. We're here to help you make informed investment decisions today.

FIND US ON

Receive our IMNM Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

IMNM Stock trends

IMNM Stock performance

IMNM Stock analysis

IMNM investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing IMNM

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing IMNM

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

IMNM Stock Analysis & IQ Rating | Immunome

IMNM Stock IQ

IMNM Target Price

IMNM Risk Level

IMNM Analysts Opinion

IMNM Street Sentiment

IMNM Performance Sentiment

Technical Price Levels

Explore our IMNM Stock insights

Receive our IMNM Daily Alerts

IMNM Street Sentiment

IMNM Risk Level

Technical Price Levels

Discover IMNM Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of IMNM. We're here to help you make informed investment decisions today.

Receive our IMNM Daily Alerts

IMNM Alerts